Pharmaron Beijing Co Ltd

Pharmaron Beijing Co Ltd

300759 · SHE · Healthcare / Biotechnology

42.43CNY-1.73 (-3.92%)

Price History

Full chart

Market Stats

Previous Close44.16
Open43.57
Day Range42.23 – 44.04
52-Week Range20.87 – 53.57
Volume41.71M
Market Cap82.62B
P/E (TTM)47.34
Forward P/E30.21
EPS0.95
Dividend Yield0.44%
Beta0.64
50-Day Avg43.26
200-Day Avg32.40

About

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Boliang Lou Ph.D.
  • Employees27.32K
  • HeadquartersBuilding 1, Beijing, China, 100176, China
  • Websitehttps://www.pharmaron.com

Leadership

  • Dr. Boliang Lou Ph.D.Chairman & CEO · b. 1963
  • Mr. Xiaoqiang Lou EMBACo-Founder, President, COO & Executive Director · b. 1968
  • Mr. Shing Chung Li C.F.A., CPACFO, Secretary of the Board, Accounting Supervisor & Employee Representative Director · b. 1978
  • Dr. Hua Yang Ph.D.Chief Scientific Officer & Deputy Manager · b. 1962
  • Ms. Bei Zheng M.A.Executive VP & Executive Director · b. 1967
  • Dr. Connie Sun Ph.D.Senior VP & Global Head of Business Development of Small Molecules
  • Ms. Celina Zhong M.B.A.Senior Vice President of Human Resources
  • Ms. Katherine Lee M.B.A.Chief Business Officer
  • Mr. Stephen LewintonSenior Vice President of UK Operations
  • Dr. Jingqi HuangSenior Vice President of In Vivo Pharmacology

Financials

Income Statement

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue790.44M1.13B1.63B2.29B2.91B3.76B5.13B7.44B10.27B11.54B12.28B14.10B
Growth (%)-+42.71%+44.87%+40.38%+26.76%+29.20%+36.64%+45.00%+37.92%+12.39%+6.39%+14.82%
Cost of Revenue592.09M817.64M1.16B1.52B1.96B2.42B3.21B4.77B6.50B7.42B8.09B9.19B
Gross Profit198.35M310.40M474.01M772.44M949.99M1.33B1.92B2.68B3.76B4.12B4.18B4.91B
Gross Margin25.09%27.52%29.00%33.67%32.67%35.49%37.38%35.95%36.67%35.67%34.09%34.83%
Operating Expense173.73M237.49M284.17M509.47M557.41M701.87M595.06M761.74M2.07B2.27B2.08B2.68B
Operating Income24.61M72.91M189.84M262.97M392.58M631.49M1.32B1.91B1.69B1.85B2.10B2.22B
Operating Margin3.11%6.46%11.62%11.46%13.50%16.81%25.79%25.72%16.46%16.02%17.14%15.78%
EBITDA92.74M149.11M280.89M504.32M640.95M928.02M1.32B1.85B2.23B2.43B2.58B3.29B
EBITDA Margin11.73%13.22%17.19%21.98%22.04%24.70%25.81%24.88%21.70%21.07%21.04%23.32%
Net Income21.00M73.85M176.91M230.86M333.04M547.19M1.17B1.66B1.37B1.60B1.79B1.66B
Net Income Margin2.66%6.55%10.83%10.06%11.45%14.56%22.84%22.31%13.39%13.88%14.61%11.80%
R&D--16.44M22.61M31.61M62.87M105.35M151.77M282.32M448.28M469.26M576.02M
R&D as % of Total Revenue--1.01%0.99%1.09%1.67%2.05%2.04%2.75%3.89%3.82%4.09%
Interest Expense13.78M17.55M18.06M61.39M73.12M82.48M25.21M84.46M167.31M182.19M243.72M192.81M
Interest Expense % of Total Revenue1.74%1.56%1.10%2.68%2.51%2.20%0.49%1.13%1.63%1.58%1.99%1.37%

Balance Sheet

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets931.46M1.17B2.80B3.92B4.80B9.94B11.91B18.39B20.49B26.48B23.93B27.09B
Total Liabilities673.22M1.01B1.04B1.91B2.48B2.10B2.98B8.09B9.65B13.24B9.70B11.36B
Total Equity258.25M168.43M1.76B2.00B2.31B7.77B8.87B10.13B10.55B12.56B13.62B15.06B
Cash41.02M87.05M470.21M305.50M320.71M4.46B2.94B3.54B1.50B5.92B1.69B1.02B
Total Debt158.54M172.78M526.06M1.10B1.40B887.14M958.68M5.13B5.88B9.36B5.54B-
Net Debt117.52M85.73M55.85M799.06M1.08B-3.57B-1.98B1.59B4.38B3.44B3.85B2.02B

Cash Flow

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow12.13M216.94M235.77M552.22M790.75M938.59M1.65B2.06B2.14B2.75B2.58B3.22B
Investing Cash Flow-81.93M-480.89M-1.14B-1.28B-714.60M-1.05B-3.37B-5.26B-2.21B-1.35B-2.02B-
Financing Cash Flow42.10M298.13M1.28B572.23M-69.05M4.25B-280.18M3.66B-1.42B3.92B-4.80B-
Capital Expenditure81.94M258.32M1.06B934.67M640.99M754.61M1.32B2.09B2.95B2.87B2.04B2.67B
Free Cash Flow-69.80M-41.38M-819.72M-382.45M96.27M183.98M332.77M-34.78M-807.04M-111.78M536.02M551.97M
Dividends Paid14.90M15.92M14.41M60.60M74.60M72.19M119.14M237.55M404.76M444.79M542.23M531.05M
FCF to OCF-575.25%-19.08%-347.68%-69.26%12.17%19.60%20.18%-1.69%-37.66%-4.06%20.80%17.14%
Dividend Paid to FCF-21.34%-38.47%-1.76%-15.84%77.48%39.24%35.80%-683.04%-50.15%-397.91%101.16%96.21%

Earnings

Report DateApr 29, 2019Aug 15, 2019Oct 25, 2019Feb 28, 2020Apr 28, 2020Aug 26, 2020Oct 28, 2020Mar 28, 2021Apr 28, 2021Aug 29, 2021Oct 27, 2021Mar 10, 2022Apr 28, 2022Aug 29, 2022Oct 27, 2022Mar 30, 2023Apr 27, 2023Aug 27, 2023Oct 29, 2023Mar 27, 2024Apr 25, 2024Aug 27, 2024Oct 29, 2024Mar 26, 2025Apr 25, 2025Aug 21, 2025Oct 28, 2025Mar 30, 2026Apr 25, 2026Aug 20, 2026
EPS Estimate----0.06-0.160.16----0.220.220.22--0.260.270.180.200.210.260.260.170.260.230.280.210.24
EPS Actual0.050.090.170.330.060.320.140.130.310.270.400.490.210.280.320.350.300.230.200.260.100.160.180.190.160.200.230.290.290.23
Surprise----0.00%--12.50%-18.75%-----4.55%27.27%45.45%---11.54%-25.93%44.44%-50.00%-23.81%-30.77%-26.92%-3.29%-23.08%0.00%3.57%40.05%-4.17%
TimingPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap82.62B
Enterprise Value80.41B
Trailing P/E47.34
Forward P/E30.21
Price / Sales5.42
Price / Book5.06
EPS0.95
Book Value8.93
Revenue (TTM)15.25B
Gross Profit (TTM)5.19B
EBITDA3.22B
Profit Margin11.23%
Operating Margin13.40%
Return on Equity10.11%
Return on Assets4.87%
Shares Outstanding1.48B
Shares Float1.26B
Beta0.64
Dividend Yield0.44%
Dividend Rate0.20
Payout Ratio19.16%

Dividends

20261×
0.20Jul 7, 2026
20251×
0.20Jul 4, 2025
20241×
0.20Jun 27, 2024
20231×
0.30Jul 27, 2023
20221×
0.30Jun 14, 2022
20211×
0.13Jun 30, 2021
20201×
0.07Jul 15, 2020
20191×
0.05Jul 8, 2019

Stock Splits

  • Jul 27, 20231.5:1
  • Jun 14, 20221.5:1